Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6698MR)

This product GTTS-WQ6698MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6698MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3147MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ15760MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ1593MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ4842MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ1700MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ8761MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ2654MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ13803MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-10933
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW